Trials / Completed
CompletedNCT00863174
A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma
A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of SPARC_147709- Test and Reference, 2mg/ml (30 mg/m2 Dose) in Patients With Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Sun Pharma Advanced Research Company Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Safety and bioequivalence of SPARC\_147709
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPARC147709 | SPARC147709 injection |
| DRUG | Reference147709 | Reference147709 injection |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-01-01
- Completion
- 2011-04-01
- First posted
- 2009-03-17
- Last updated
- 2019-05-03
Source: ClinicalTrials.gov record NCT00863174. Inclusion in this directory is not an endorsement.